Abstract
Get full access to this article
View all access options for this article.
References
1.Bluebird bio (2014 a). bluebird bio acquires Precision Genome Engineering (Pregenen) . Available at http://investor.bluebirdbio.com/phoenix.zhtml?c=251820&p=irol-newsArticle&ID=1943834&highlight= (accessed
July 11 , 2014
).
2.Bluebird bio (2014 b). bluebird bio reports rapid transfusion independence in beta-thalassemia major patients treated with its LentiGlobin product candidate . Available at http://investor.bluebirdbio.com/phoenix.zhtml?c=251820&p=irol-newsArticle&ID=1939867&highlight= (accessed
July 11 , 2014
).
3.Cardium Therapeutics (2014 ). Cardium announces positive interim phase 3 clinical data showing significant efficacy of Generx® angiogenic gene therapy for myocardial ischemia due to coronary artery disease at the 2014 BIO International Convention . Available at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-newsArticle&ID=1942146&highlight= (accessed
July 11 , 2014
).
4.Dimension Therapeutics (2014 ). Dimension Therapeutics and Bayer HealthCare enter collaboration to develop novel gene therapy for hemophilia A . Available at http://dimensiontx.com/pdfs/Dimension%20-%20Bayer%20Release%206.20.14.pdf (accessed
July 11 , 2014
).
5.
Gaffney
A
. (2014 ). FDA wants sponsors of biotech products to assess product's impact on environment . Available at www.raps.org/regulatory-focus/news/2014/06/19566/Environmental-Assessment-for-Biotechnology-Products/ (accessed
July 30 , 2014
)
6.U.S. Food and Drug Administration (2014 ). Draft guidance for industry: determining the need for and content of environmental assessments for gene therapies, vectored vaccines, and related recombinant viral or microbial products . Available at www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM402063.pdf (accessed
July 11 , 2014
).